Učitavanje...

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma

The hepatocyte growth factor/c-MET pathway has been implicated in the pathobiology of multiple myeloma, and c-MET inhibitors induce myeloma cell apoptosis, suggesting that they could be useful clinically. We conducted a phase II study with the c-MET inhibitor tivantinib in patients with relapsed, or...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Hematol
Glavni autori: Baljevic, Muhamed, Zaman, Shadia, Baladandayuthapani, Veerabhadran, Lin, Yan Heather, de Partovi, Claudia Morales, Berkova, Zuzana, Amini, Behrang, Thomas, Sheeba K., Shah, Jatin J., Weber, Donna M., Fu, Min, Cleeland, Charles S., Wang, Xin Shelley, Stellrecht, Christine M., Davis, Richard E., Gandhi, Varsha, Orlowski, Robert Z.
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2017
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5406425/
https://ncbi.nlm.nih.gov/pubmed/28337527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-017-2980-3
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!